Loading quotes...
Forecast
The analysts' average price target is €8.45 (+2,183.78%). The median is €8.45 (+2,183.78%).
| Buy |
13 |
| Hold |
5 |
| Sell |
2 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 29.29m | 8.97% |
| Gross profit | 28.34m | 9.41% |
| Net profit | -58.73m | 85.81% |
| EBITDA | -47.21m | 114.80% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €7.71m |
Number of shares | 22.68m |
52-week high/low | €9.78 - €0.28 |
| Dividends | No |
Beta | 1.04 |
P/E ratio | -0.02 |
PEG ratio | 0.00 |
P/B ratio | -0.03 |
P/S ratio | 0.06 |
Company profile
| Name | Karyopharm Therapeutics |
| CEO | Richard A. Paulson |
| Employees | 228 |
